
More Americans are identifying as neurodivergent. So why are work accommodations becoming more stigmatized?
While estimates of the percentage of neurodivergent people globally typically range from 15–20%, new survey results from neurodiversity advocacy and support nonprofit Understood suggest that the true percentage of neurodivergent adults may be higher.
For one, more people are being diagnosed with ADHD and autism and other conditions that fall under the umbrella of neurodivergence. But more people may also be self-identifying as neurodivergent—especially in younger generations. Deloitte's 2023 Gen Z and Millennial Survey showed that 53% of Gen Z self-identify as neurodivergent.
'The people who identify or have symptoms of [neurodivergence], will far exceed the most conservative estimate of those who have been actually diagnosed,' says Nathan Friedman, copresident and chief marketing officer of Understood. He suggests that barriers such as high psychiatry costs and the misdiagnosis of neurodivergent women might prevent individuals from pursuing (or acquiring) a formal diagnosis.
In April, Understood conducted a weighted survey of over 2000 U.S. adults, 659 of whom identify as neurodivergent. Thirty-one percent of respondents had at least wondered if they were neurodivergent although only 11% had received an official diagnosis.
Stigma around requesting accommodations
In a recent ResumeGenius poll of 1000 hiring managers, 86% claim that disclosing neurodivergence in an application would have either a positive or neutral effect on their hiring decision.
But Understood's research suggests that neurodivergent workers have real concerns. In the survey, 64% of employed U.S. adults agree that people speak about their neurodivergence at work more openly now, but 70% agree there's a stigma around asking for workplace accommodations. That's a 10% increase from their results last year.
Among those workers who have requested accommodations, only 56% received ones that actually improved their work experience. One in four got accommodations that weren't helpful, one in five were outright denied, and nearly one in five later regretted asking.
'Asking for accommodations doesn't necessarily mean you're unable to perform or you're unable to achieve the results of what's expected,' says Friedman. The accommodations that workers typically ask for are simple to implement, he says. 'Accommodations could be anything from a flexible work environment to changing desks . . . [These] are pretty simple things that can help somebody improve how they work, the output of their work, and their feeling about how they work.'
Despite this, 15% of respondents said they had lost a job, were demoted, or lost a job opportunity after asking for accommodations. Part of this increase in perceived stigma may be connected with the Trump administration's attacks on DEI in the workplace. In fact, the survey results show that 64% of U.S. adults believe DEI program rollbacks will make it more difficult for people to access workplace accommodations. 'Difference right now is not seen as a good thing—regardless of where you're at,' says Friedman.
What can be done
Reducing stigma and improving the efficacy of workplace accommodations starts with proper education about neurodivergence in the workplace. 'We hear so many stories about individuals who don't have the right accommodations and are let go because they don't have what's needed to do their job,' says Friedman. 'So providing the education, providing the pathway to get an accommodation, and delivering the accommodations are all required.'
This is especially crucial as Gen Z now outnumbers boomers in the workplace. 'Over 50% of Gen Z believes they are neurodivergent,' says Friedman. 'If you're a company of 10,000 people, that's upwards of 5,000 people that you could get a better work product from. . . . So [offering accommodations] is a win for everyone.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Los Angeles Times
11 hours ago
- Los Angeles Times
Tourette Syndrome: A Look at Today's Best Treatments
Tourette syndrome (TS) is more than just a childhood phase of twitching or making sounds—it's a chronic neurodevelopmental condition that can disrupt daily functioning and emotional well-being. Characterized by both motor and vocal tics that begin before age 18 and last for more than a year, Tourette's often brings along other challenges like ADHD, obsessive-compulsive disorder (OCD), and anxiety. While some kids see symptoms lessen as they age, others need long-term, individualized treatment plans to manage both the tics and associated psychiatric conditions. Tourette syndrome is diagnosed when an individual has at least two motor tics and one vocal tic for more than 12 months, with onset before age 18 [1]. These tics are sudden, repetitive, and involuntary—for example, blinking, throat clearing, or shoulder shrugging. A helpful diagnostic clue is that people with TS can often suppress their tics briefly, unlike those with habit cough or psychogenic cough [1]. Differentiating TS from other movement or psychiatric disorders is key, especially since tics can wax and wane in intensity. That fluctuation, combined with the ability to voluntarily hold back tics for short periods, helps set Tourette's apart from conditions like dystonia or chorea. Behavioral therapy is the foundation of TS treatment, and CBIT is the gold standard. This structured approach combines habit reversal training with relaxation techniques and functional intervention strategies. CBIT helps individuals recognize premonitory urges—the sensations that precede tics—and teaches them to respond with competing behaviors that prevent the tic. CBIT has been shown to be effective across different delivery formats. A 2024 review found it worked in both in-person and telehealth settings—even when ADHD or OCD were present [4]. In fact, recent studies show that tele-CBIT sessions are almost as effective as in-office visits [5], making it a convenient option for families with busy schedules or living far from specialists. Medications like clonidine and guanfacine are often used for kids with mild to moderate tics—especially when ADHD is also present. These medications work on the brain's norepinephrine pathways to reduce hyperactivity and impulsivity which in turn can reduce tic severity. Their appeal is their safety profile. Compared to antipsychotics, alpha-2 agonists are less likely to cause serious side effects, making them a good starting point for young patients [2] [3]. When behavioral therapy and alpha-agonists don't work, antipsychotic medications may be added. These drugs target dopamine pathways—known to be involved in tic generation—but come with trade-offs. Aripiprazole and risperidone are commonly prescribed because they are better tolerated than older drugs like haloperidol. Meanwhile pimozide, a dopamine receptor blocker, has shown better outcomes than haloperidol in clinical trials [1]. For individuals with focal tics—like persistent eye blinking or neck movements—botulinum toxin injections can provide targeted relief by weakening overactive muscles [6]. Despite their effectiveness, antipsychotics require close monitoring. Side effects like sedation, weight gain, and movement disorders (e.g., tardive dyskinesia) can emerge especially with long-term use. Clinicians must weigh the benefits of symptom relief against the risk of side effects and adjust treatment accordingly [3]. For the small percentage of individuals with treatment-refractory TS, Deep Brain Stimulation (DBS) may be considered. DBS involves surgically implanting electrodes into specific brain regions to modulate abnormal activity. While still relatively rare and not standard care, DBS has shown promising results in reducing severe tics in select patients [6]. Beyond medical interventions, holistic care is key. Support groups, patient education and school-based accommodations—like extended test times or breaks during class—can make a big difference in a child's social and academic success. TS isn't just about the tics—it's about the whole person. Comorbidities like OCD, ADHD, and anxiety often impact daily life more than the tics themselves. So treatment plans must be individualized and medication choices should consider these overlapping conditions [2]. Clinicians must also distinguish tics from other movement disorders. Features like premonitory urges, voluntary suppression and the episodic nature of tics can help differentiate TS from other hyperkinetic disorders [1]. Tourette syndrome may be lifelong but it doesn't have to be life defining. With the right combination of behavioral therapy, medication, support and education most people can manage their symptoms and live well. As research advances—especially in digital therapy delivery and neuromodulation—there's more hope for more personalized, accessible and effective treatments for people with TS. [1] Irwin, R. S., Glomb, W. B., & Chang, A. B. (2006). Habit cough, tic cough, and psychogenic cough in adult and pediatric populations: ACCP evidence-based clinical practice guidelines. Chest, 129(1 Suppl), 174S–179S. [2] Egolf, A., & Coffey, B. J. (2014). Current pharmacotherapeutic approaches for the treatment of Tourette syndrome. Drugs of today (Barcelona, Spain : 1998), 50(2), 159–179. [3] Whittington, C., Pennant, M., Kendall, T., Glazebrook, C., Trayner, P., Groom, M., Hedderly, T., Heyman, I., Jackson, G., Jackson, S., Murphy, T., Rickards, H., Robertson, M., Stern, J., & Hollis, C. (2016). Practitioner Review: Treatments for Tourette syndrome in children and young people - a systematic review. Journal of child psychology and psychiatry, and allied disciplines, 57(9), 988–1004. [4] Kohler, K., Rosen, N., & Piacentini, J. (2025). Description, Implementation, and Efficacy of the Comprehensive Behavioral Intervention for Tics as First-Line Treatment for Tourette and Other Tic Disorders. Journal of child and adolescent psychopharmacology, 35(3), 126–134. [5] Morand-Beaulieu, S., Szejko, N., Fletcher, J., & Pringsheim, T. (2024). Behavioural Therapy for tic disorders: a comprehensive review of the literature. Expert review of neurotherapeutics, 24(12), 1181–1191. [6] Billnitzer, A., & Jankovic, J. (2020). Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 17(4), 1681–1693.


Time Business News
12 hours ago
- Time Business News
Strattera vs Adderall: Which Works Faster for ADHD?
When it comes to treating ADHD (Attention Deficit Hyperactivity Disorder), both Strattera and Adderall are commonly prescribed medications. But a question many people ask is: Which one works faster? While both drugs can be effective in managing ADHD symptoms, they work in very different ways—and their speed of effectiveness reflects that. In this article, we'll break down how quickly strattera vs adderall start working, what affects their performance, and which might be a better choice depending on your needs. When considering treatment for anxiety or depression, selecting the right medication is crucial. Both medications have proven effective, but individual response may vary based on body chemistry and side effects. In the debate of Lexapro vs Zoloft, Lexapro is often praised for its smoother onset and fewer initial side effects, while Zoloft may be preferred for treating a wider range of conditions, including PTSD and OCD. Consulting a healthcare professional can help tailor the right approach, as factors like medical history and lifestyle play an essential role in determining the most suitable antidepressant. Before diving into how fast each medication works, it's important to understand what each drug is and how it functions: Adderall is a stimulant medication made up of amphetamine salts. It increases the levels of dopamine and norepinephrine in the brain—neurotransmitters associated with attention and focus. Adderall comes in two forms: immediate-release (IR) and extended-release (XR). Strattera (atomoxetine), on the other hand, is a non-stimulant medication. It works by selectively inhibiting the reuptake of norepinephrine, a different mechanism that takes more time to affect brain chemistry compared to stimulants. If you're looking for immediate symptom relief, Adderall is the faster option—hands down. Most people begin to feel its effects within 30 to 60 minutes after taking a dose. The immediate-release version typically lasts about 4–6 hours, while the extended-release form can last 10–12 hours. This makes Adderall an ideal choice for individuals who need quick and predictable symptom control, such as students or professionals who need to focus at specific times of day. Strattera doesn't work right away. In fact, it can take 2 to 4 weeks before noticeable improvements in focus or behavior occur, and up to 6–8 weeks for full benefits to kick in. This delay can be frustrating for individuals hoping for a rapid change. However, Strattera has its own advantages—it provides 24-hour coverage, and since it's not a stimulant, it may be better suited for those with coexisting anxiety, substance abuse history, or sleep issues. The faster effect of Adderall comes from how it directly boosts dopamine and norepinephrine levels almost immediately after ingestion. This sharp increase helps improve focus, reduce impulsivity, and calm hyperactivity in a short time frame. Strattera, on the other hand, gradually increases norepinephrine by preventing its reabsorption in the brain. This slow build-up is why it takes longer to feel the effects. However, this gradual adjustment can also lead to fewer emotional crashes or 'come-down' periods that some Adderall users experience. The speed of relief isn't the only factor to consider when choosing between Strattera and Adderall. Each has its own side effect profile: Adderall side effects can include insomnia, appetite suppression, jitteriness, increased heart rate, and the risk of dependence or misuse. Strattera may cause drowsiness, nausea, dry mouth, or mood swings—though it doesn't carry the same risk of addiction. People with coexisting anxiety or a history of substance misuse often tolerate Strattera better, even if it's slower to act. In contrast, someone who needs rapid symptom control during work or school hours might lean toward Adderall despite the side effect risks. Short-Term Goals: If the immediate goal is to improve focus for a test, meeting, or daily function, Adderall offers clear benefits thanks to its fast-acting nature. Long-Term Stability: For individuals looking for consistent, around-the-clock symptom control without the highs and lows of stimulant medication, Strattera may be the better fit—even though you'll need to be patient with the results. In some cases, doctors may even prescribe both medications at different times of day or for different symptom profiles. But this is done under close medical supervision. Choosing between Strattera and Adderall depends on your individual needs, health history, and treatment goals. Here are some questions to consider: Do you need fast results? Do you have a history of anxiety or substance abuse? Are you okay with taking a medication daily and waiting several weeks to feel the full effect? Do you need 24-hour symptom control? Always discuss these questions with your healthcare provider. They can help you weigh the benefits and drawbacks of each medication based on your personal circumstances. So, which works faster for ADHD—Strattera or Adderall? The clear winner in terms of speed is Adderall. It can start working in less than an hour and provide sharp symptom control for several hours. However, that quick relief comes with a higher potential for side effects and dependency. Strattera may take weeks to kick in, but for the right individual, it can offer consistent, all-day symptom relief without the crash or addiction risks associated with stimulants. Both medications have their place in ADHD treatment. The best choice isn't just about speed—it's about what works best for you in the long run. TIME BUSINESS NEWS
Yahoo
14 hours ago
- Yahoo
Excellent Brain Ltd. Announces Joint Venture with MasNeuros to Launch Spanish Neurofeedback Trainers Course
Excellent Brain Ltd. Expands Global Reach with Spanish Neurofeedback Course Natanya, Israel , June 18, 2025 (GLOBE NEWSWIRE) -- Excellent Brain Ltd., an innovative Israeli start-up renowned for its advanced neurofeedback solutions, has announced a strategic joint venture with MasNeuros, a leading Spanish organization. This collaboration aims to deliver the Excellent Brain's Trainers Course in Spanish, focusing on Neurofeedback for ADHD, utilizing the cutting-edge Excellent Brain Neurofeedback Brain - Neurofeedback for ADHDThe first course, successfully completed in May 2025, marks a significant milestone in making neurofeedback training accessible to Spanish-speaking clinics. This initiative is set to empower healthcare professionals across Spanish-speaking countries, providing them with the most effective tools for managing ADHD in clinical settings. Ofer A. Lidsky, CEO and founder of Excellent Brain Ltd., expressed his enthusiasm for the collaboration, stating, "Partnering with MasNeuros allows us to extend our innovative neurofeedback training to a broader audience. This joint venture is a testament to our commitment to enhancing cognitive health and providing accessible solutions for ADHD management worldwide." The Excellent Brain Neurofeedback platform is celebrated for its ability to leverage EEG signal processing to enhance brain function. By offering training programs that improve various cognitive aspects, particularly for individuals with ADHD, the platform stands as a beacon of innovation in mental wellness and cognitive enhancement. This joint venture not only broadens the reach of Excellent Brain's pioneering technology but also reinforces its position as a leader in the field of neurofeedback. By collaborating with MasNeuros, Excellent Brain Ltd. is poised to make a significant impact on the mental health landscape in Spanish-speaking regions. The completion of the first course signifies the beginning of a new era in neurofeedback training, where language is no longer a barrier to accessing world-class cognitive enhancement tools. Clinics in Spanish-speaking countries can now integrate these advanced solutions into their practices, offering patients the benefits of cutting-edge ADHD management Training for improving ADHD symptomsAbout Excellent Brain Ltd. Excellent Brain Ltd., founded in 2015 by entrepreneur Ofer A. Lidsky, is an innovative Israeli start-up specializing in advanced neurofeedback solutions. The company's cutting-edge platform leverages EEG signal processing to enhance brain function, offering accessible training programs aimed at improving various cognitive aspects, particularly for individuals with ADHD. Excellent Brain's technology enables users to engage in neurofeedback and virtual reality-based training, promoting mental wellness and cognitive enhancement. Press inquiries Excellent Brain Ltd. Ofer Lidsky ofer@ A video accompanying this announcement is available at in to access your portfolio